Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: Pathophysiologic foundation and clinical findings AMERICAN HEART JOURNAL Kleiman, N. S., Lincoff, A. M., Ohman, E. M., Harrington, R. A. 1998; 136 (4): S32-S42

Abstract

The pathophysiologic basis for potent platelet inhibition in the acute coronary syndromes has been established. In the setting of PTCA for unstable angina and non-Q-wave myocardial infarction, there are clear data for a benefit of GP IIb/IIIa inhibition, whereas for primary PTCA in evolving myocardial infarction, preliminary data are very encouraging and a large-scale clinical trial is nearly completed. Glycoprotein IIb/IIIa inhibition as an adjunct to medical therapy for unstable angina is also the subject of encouraging preliminary data, and 3 large-scale clinical trials have just been completed. Preliminary data have also been accrued for GP IIb/IIIa inhibition as conjunctive therapy with thrombolytic agents, and large clinical trials are now commencing.

View details for Web of Science ID 000076408000004

View details for PubMedID 9778086